#Sovaldi

The Supreme Court refused to hear Merck’s arguments on a hepatitis C patent, so the previous ruling in Gilead’s favor stands.

Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.

In a recent British Columbia study, 1 in 10 people who began treatment were lost to follow-up.

Though low, this figure is three times the rate of discontinuation seen in clinical trials.

Danish researchers followed 71 people who were cured with Sovaldi-based treatment.

A recent mid-stage trial that combined coblopasvir with Sovaldi (sofosbuvir) boasted a high cure rate.

A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

September 4, 2019, the U.S. FDA released their recent approval of new dosage forms of Sovaldi and Harvoni for children 3 to 12 years of age.

Health advocate David Whiters has mastered some smooth moves since overcoming addiction and hep C.

The presence of less studied HCV genotypes may compromise cure rates.

Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.

The VA has cured HCV in nearly 100,000 veterans, which will dramatically reduce the development of advanced liver disease and liver cancer.

Las Vegas resident Stella Armstrong cured her hep C and the joy-killing fatigue and pain that came with it.

Researchers compared outcomes among those with and without hep C before and after Sovaldi was approved in late 2013.

These drugs are approved to treat all six major genotypes of hepatitis C.